HARVONI90mg/400mg

HARVONI by Gilead Sciences revolutionized Hepatitis C treatment as the first single-tablet, all-oral regimen — eliminating the need for interferon injections and their severe side effects. This fixed-dose combination of Ledipasvir (an NS5A inhibitor) and Sofosbuvir (a nucleotide NS5B polymerase inhibitor) achieves cure rates (SVR12) of 94-99% across landmark ION clinical trials. With over 1.5 million patients treated worldwide since FDA approval in October 2014, Harvoni has one of the most extensive real-world safety and efficacy databases of any antiviral medication. Treatment duration is typically 8-12 weeks for most patients, transforming what was once a chronic, debilitating disease requiring 48 weeks of difficult therapy into a simple oral cure. Working through licensed Turkish pharmacy channels, we provide authentic Gilead Harvoni with full batch traceability, batch and expiry documentation, and a written quote against a prescription, usually within 24 hours for hospitals, hepatology clinics, government health programs, and pharmaceutical distributors worldwide.